Latest Genovis News & Updates
See the latest news and media coverage for Genovis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company specializing in protein analysis tools
genovis.com- Headquarters
- Kävlinge, Sweden
- Founded year
- 1999
- Company type
- Public company
- Number of employees
- 40–50
Last updated
Latest news about Genovis
In short: Genovis expanded its genomics and ADC capabilities through strategic license agreements, the acquisition of SEQURNA, and several product launches.
Company announcements
-
Genovis reports 4% net sales growth for Q1 2026
Net sales reached SEK 33,506 thousand. EBITDA improved to SEK 9,510 thousand. Launched LysCERATOR™ and SEQguard™. Signed ADC license deal.
-
Genovis summons shareholders to AGM
The meeting occurs on May 18, 2026, at 5:00 p.m. in Kävlinge. Proposals cover board elections, fees, auditors, remuneration guidelines, and share issue authorizations.
-
Genovis and Plasmidsaurus launch SEQguard™ Dino Preserve
The product enables ambient-temperature RNA shipping for next-generation sequencing, reducing costs and carbon footprint. It integrates with Plasmidsaurus' workflows.
-
Genovis enters non-exclusive license agreement for EndoS2 technology
The US biotech licensee gains worldwide rights for ADC research, development, and commercialization. Genovis receives upfront and milestone payments up to USD 20 million per program.
Media coverage
-
Genovis AB publishes Annual Report 2025 — TradingView News
Genovis' innovative products and technologies are used by scientists all over the world and the product formats streamline and improve workflows in biochemical analysis and...
-
Plasmidsaurus Accelerates RNA-Seq: New EU Hub and Genovis Partnership Adds Stability to Speed, Without the Ice
Plasmidsaurus, the leading Sequencing as a Service company, has announced two transformative evolutions of its RNA-Seq ecosystem: the launch of a high-capacity RNA sequencing hub...
-
Affärsvärlden gives buy recommendation for Genovis
Affärsvärlden gives buy recommendation for the biotech company Genovis in an analysis on Thursday.
-
Genovis Enters Non-Exclusive License Agreement for EndoS2 Enzyme Technology for Antibody-Drug Conjugate (ADC) Development and Commercialization
Genovis AB announces that it has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis’ proprietary...
Track Genovis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Genovis competitors & trending companies
Browse news for competitors to Genovis and other trending companies.
Bio-Techne
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove